More than an accessory: implications of type III transforming growth factor-β receptor loss in prostate cancer

被引：15

作者：

Ajiboye, Seun ^{[2
]}

Sissung, Tristan M.

Sharifi, Nima ^{[3
]}

Figg, William D. ^{[1
,2
]}

机构：

[1] NCI, Clin Pharmacol Program, Med Oncol Clin Res Unit, Med Oncol Branch,Ctr Canc Res, Bethesda, MD 20892 USA

[2] NCI, Mol Pharmacol Sect, Bethesda, MD 20892 USA

[3] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Hematol & Oncol, Dallas, TX USA

来源：

BJU INTERNATIONAL | 2010年 / 105卷 / 07期

基金：

美国国家卫生研究院;

关键词：

betaglycan; TGF beta III receptor; prostate cancer; testosterone; TUMOR-SUPPRESSOR; CELL-MIGRATION; BETAGLYCAN; ACTIVINS; INHIBINS; ACTIVATION; EXPRESSION;

D O I：

10.1111/j.1464-410X.2009.08999.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The type III transforming growth factor-beta receptor (TGF beta R3, betaglycan), a tumour suppressor, is the most frequently lost TGF beta pathway component. This event appears to be very important in the transition of the TGF beta pathway from having tumour-suppressor activity in early prostate tumour development, to having tumour-promoting activity in metastatic disease. Moreover, loss of the TGF beta R3 can also affect the cellular response towards testosterone, inhibin/activin, and dysregulate growth-factor pathways that mediate growth and angiogenesis. In this review we discuss how TGF beta R3 normally functions as an accessory protein in the TGF beta pathway, how its loss is related to tumour progression, and the treatment implications of TGF beta R3 loss in individuals with prostate cancer.

引用

页码：913 / 916

页数：4

共 21 条

[11] The type III TGF-β receptor regulates epithelial and cancer cell migration through β-arrestin2-mediated activation of Cdc42 [J].

Mythreye, Karthikeyan ;

Blobe, Gerard C. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (20) :8221-8226

[12] Activins and inhibins in endocrine and other tumors [J].

Risbridger, GP ;

Schmitt, JF ;

Robertson, DM .

ENDOCRINE REVIEWS, 2001, 22 (06) :836-858

[13] The contribution of inhibins and activins to malignant prostate disease [J].

Risbridger, GP ;

Mellor, SL ;

McPherson, SJ ;

Schmitt, JF .

MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2001, 180 (1-2) :149-153

[14] Androgen deprivation therapy for prostate cancer [J].

Sharifi, N ;

Gulley, JL ;

Dahut, WL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (02) :238-244

[15] Transforming growth factor-β receptor III downregulation in prostate cancer:: is inhibin B a tumor suppressor in prostate? [J].

Sharifi, Nima ;

Lechleider, Robert J. ;

Farrar, William L. .

JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2007, 39 (5-6) :329-332

[16] TGFBR3 loss and consequences in prostate cancer [J].

Sharifi, Nima ;

Hurt, Elaine M. ;

Kawasaki, Brian T. ;

Farrar, William L. .

PROSTATE, 2007, 67 (03) :301-311

[17] Mechanisms of TGF-β signaling from cell membrane to the nucleus [J].

Shi, YG ;

Massagué, J .

CELL, 2003, 113 (06) :685-700

[18] Activin Receptor Signaling Regulates Prostatic Epithelial Cell Adhesion and Viability [J].

Simon, Derek P. ;

Meethal, Sivan Vadakkadath ;

Wilson, Andrea C. ;

Gallego, Miguel J. ;

Weinecke, Stephanie L. ;

Bruce, Erin ;

Lyons, Patrick ;

Haasl, Ryan ;

Bowen, Richard L. ;

Atwood, Craig S. .

NEOPLASIA, 2009, 11 (04) :365-U72

[19] EXPRESSION OF TRANSFORMING GROWTH-FACTOR-BETA-1 IN PROSTATE-CANCER [J].

STEINER, MS ;

ZHOU, ZZ ;

TONB, DC ;

BARRACK, ER .

ENDOCRINOLOGY, 1994, 135 (05) :2240-2247

[20] The type III transforming growth factor-β receptor as a novel tumor suppressor gene in prostate cancer [J].

Turley, Ryan S. ;

Finger, Elizabeth C. ;

Hempel, Nadine ;

How, Tam ;

Fields, Timothy A. ;

Blobe, Gerard C. .

CANCER RESEARCH, 2007, 67 (03) :1090-1098

← 1 2 3 →